

Company	FR docket	Published
Patheon API Manufacturing, Inc.	83 FR 58596	November 20, 2018.
Insys Manufacturing, LLC	83 FR 60899	November 27, 2018.
Cayman Chemical Company	83 FR 60900	November 27, 2018.
Noramco Inc.	83 FR 60898	November 27, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of the listed registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR

1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Dated: February 18, 2019.
John J. Martin,
Assistant Administrator.
 [FR Doc. 2019-04033 Filed 3-5-19; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of schedule I controlled substances.

SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

Company	FR Docket	Published
Insys Manufacturing, LLC	83 FR 54611	October 30, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of the listed registrant to manufacture the applicable basic classes of schedule I and II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR

1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: February 18, 2019.
John J. Martin,
Assistant Administrator.
 [FR Doc. 2019-04032 Filed 3-5-19; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as bulk manufacturer of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice.

Company	FR Docket	Published
Organix, Inc	83 FR 58601	November 20, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent

with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance

of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and